News
Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for ...
The company said its CGM+ system can deliver accurate readings across a 15-day lifespan, while also employing fewer ...
5d
Zacks Investment Research on MSNTrinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
Trinity Biotech plc TRIB announced compelling positive clinical trial results with respect to its next-generation continuous glucose monitoring (CGM) technology, CGM+, on Tuesday. The trial data ...
8d
TipRanks on MSNTrinity Biotech Announces Breakthrough in CGM Technology
An update from Trinity Biotech ( ($TRIB) ) is now available. On August 12, 2025, Trinity Biotech announced breakthrough clinical trial results for ...
Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 News provided by Trinity Biotech plc Jan 28, 2025, 7:20 AM ET ...
David Ouston, Biosensor Marketing Director of Trinity Biotech, said, “We’ve made significant progress in the development of our next generation CGM, with an innovative reimagining of our ...
-Repositioning to a rapidly expanding biosensor market with potential for significant growth for the company as part of a revised strategy under our new management -Upfront payment of $12.5 ...
Trinity Biotech (TRIB) stock gains on encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose monitoring ( (CGM)) system. Read more here.
Trinity plans to submit regulatory filings in Europe in 2025, followed by a U.S. FDA filing in 2026, and further pre-pivotal trials are set to begin in Q1 2025. TRIB closed Wednesday's (FEB.05 ...
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology Provided by GlobeNewswire Jan 28, 2025 4:20am ...
Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...
Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results